Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lucid Diagnostics Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
LUCD
Nasdaq
3841
https://www.luciddx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lucid Diagnostics Inc
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
- May 7th, 2024 11:39 am
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
- May 2nd, 2024 12:35 pm
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
- May 2nd, 2024 11:49 am
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
- Apr 29th, 2024 12:47 pm
3 Penny Stocks That Could Make a Big Comeback by the End of Q2
- Apr 19th, 2024 10:00 am
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 8th, 2024 12:30 pm
PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript
- Mar 28th, 2024 1:47 pm
Q4 2023 PAVmed Inc Earnings Call
- Mar 28th, 2024 6:00 am
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call Transcript
- Mar 27th, 2024 4:35 pm
Q4 2023 Lucid Diagnostics Inc Earnings Call
- Mar 27th, 2024 4:14 am
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
- Mar 26th, 2024 11:32 pm
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
- Mar 25th, 2024 9:30 pm
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
- Mar 21st, 2024 1:30 pm
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
- Mar 20th, 2024 12:30 pm
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
- Mar 12th, 2024 12:30 pm
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
- Feb 16th, 2024 10:00 pm
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
- Feb 15th, 2024 12:45 pm
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
- Feb 8th, 2024 12:45 pm
The 3 Most Undervalued Penny Stocks to Buy in December
- Dec 17th, 2023 8:00 pm
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
- Dec 12th, 2023 1:30 pm
Scroll